Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | HBB | P68871 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.34 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.33 |
| ▸ | GABRP | O00591 | 2/20 | 0.33 |
| ▸ | GABRD | O14764 | 2/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.33 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.33 |
| ▸ | GABRE | P78334 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3233803 | 0.90 | GABRP (0.39) | LMNAMEN1BLMHBBKMT2A | |
| SCHEMBL21433078 | 0.90 | GABRP (0.39) | LMNAMEN1BLMHBBKMT2A | |
| SCHEMBL396281 | 0.81 | LMNA (0.38) | LMNAMEN1BLMHBBKMT2A | |
| SCHEMBL397367 | 0.81 | LMNA (0.38) | LMNAMEN1BLMHBBKMT2A | |
| SCHEMBL396280 | 0.81 | LMNA (0.38) | LMNAMEN1BLMHBBKMT2A | |
| SCHEMBL3064346 | 0.81 | GSR (0.35) | — | |
| SCHEMBL2922286 | 0.81 | GSR (0.35) | — | |
| SCHEMBL17765362 | 0.79 | GSR (0.31) | — | |
| SCHEMBL17765361 | 0.79 | GSR (0.31) | — | |
| SCHEMBL12753933 | 0.79 | LMNA (0.38) | LMNAMEN1BLMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951653-B1 | SALICYLIC ACID DERIVATIVES | NICOX SA (FR) | 2010-10-20 | — | — | EP | disclosed |
| US-20080293781-A1 | Salicylic Acid Derivatives | NICOX S.A. (FR) | 2008-11-27 | — | — | US | disclosed |
| EP-1951653-A1 | SALICYLIC ACID DERIVATIVES | NicOx S.A. (FR) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007060112-A1 | SALICYLIC ACID DERIVATIVES | NICOX S.A. (FR) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293781-A1 | Salicylic Acid Derivatives | PTGS2, PTGS1, PTGES2 | LMNA 3715/4885MEN1 4722/4885BLM 3350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.